REFERENCES
- Al-Ani, A. K. (1992). A Study of CO2 Laser Cautery. MSc thesis, College of Dentistry, University of Baghdad, Baghdad, Iraq.
- Al-Mulla Hummadi, Y. M., Najim, R. A. & Al-Bashir, N. M. (2005). The mechanism behind the antileish-manial effect of zinc sulphate. I. An in-vitro study. Annals of Tropical Medicine and Parasitology, 99, 27-36.
- Chehada, A. K. & Douba, M. E. D. (1990). Treatment of cutaneous leishmaniasis. Research Journal of Aleppo University, 19, 145–160.
- Firooz, A., Khatami, A., Khameisipur, A., Nassiri-Khashani, M., Behnia, F., Niforushzadeh, M., Pazoki-Toroudi, H. & Dowlati, Y. (2005). Intra-lesional injection of 2% zinc sulfate solution in the treatment of acute Old World cutaneous leishmania-sis: a randomized, double-blind, controlled clinical trial. Journal of Drugs in Dermatology, 4,73–79.
- Iraji, F., Vali, A., Asilian, A., Shahtalebi, M. A. & Momeni, A. Z. (2004). Comparison of intralesionaly injected zinc sulfate with meglumine antimoniate in the treatment of acute cutaneous leishmaniasis. Dermatology, 209, 46–49.
- MacSween, R. N. M. & Whaley, K. (Eds) (1998). Muir's Textbook of Pathology, 13th Edn. New York, NY: Oxford University Press.
- Sereno, D., Cavaleyra, M., Zemzoumi, K., Maquaire, S., Ouaissi, A. & Lemesre, J. L. (1998). Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent anti-mony mode of action. Antimicrobial Agents and Chemotherapy, 42, 3097–3102.
- Sharquie, K. E. (1995). A new intralesional treatment of cutaneous leishmaniasis with hypertonic sodium chloride solution. Journal of Dermatology, 22,732–737.
- Sharquie, K. E. & Al-Azzawi, K. E. (1996). Intralesional therapy of cutaneous leishmaniasis with 2% zinc sulfate solution. Journal of the Pan Arab League of Dermatologists, 7, 41-46.
- Sharquie, K. E. & Al-Nuaimi, A. A. (2002). Treatment of viral warts by intralesional injection of zinc sulphate. Annals of Saudi Medicine, 22, 26-28.
- Sharquie, K. E., Al-Talib, K. & Chu, A. C. (1988). Intralesional treatment of cutaneous leishmaniasis with sodium stibogluconate antimony. British Journal of Dermatology, 119, 53–57.
- Sharquie, K. E., Najim, R A. & Farjou, I. B. (1997). A comparative control trial of intralesional administered zinc sulfate, hypertonic saline chloride and PVA compound against cutaneous leishmaniasis. Clinical and Experimental Dermatology; 22,169-173.
- Sharquie, K. E., Al-Nuaimi, A. A. & Al-Shimary, F. A. (2005). New intralesional therapy for basal cell carcinoma by 2% zinc sulphate solution. Saudi Medical Journal, 26, 359-361
- Tallab, T. M., Bahamdam, K. A., Mirdad, S., Johargi, H., Mourad, M. M., Ibrahim, K., El-Sherbini, A. H., Karkashan, E., Khare, A. K. & Jama, I. A. (1996). Cutaneous leishmaniasis: schedule for intralesional treatment with sodium stibogluconate. International Journal of Dermatology, 35, 594–597.
- Uzan, S., Durdu, M., Cuhla, G., Allahverdiyev, A. M. & Memisoglu, H. R. (2004). Clinical features, epidemiology and efficacy and safety of intralesional antimony treatment of cutaneous leishmaniasis: recent experience from Turkey. Journal of Parasitology, 90, 853–859.
- Webster Jr, L. T. (1985). Drugs used in chemotherapy of protozoa infections. In The Pharmacological Basis of Therapeutics, 7th Edn, eds Gilman, A., Goodman, L. S., Rall, T. W. & Murad, F. pp. 1029-1048. New York: MacMillan.
- World Health Organization (1984). The Leishmaniasis: Report of a WHO Expert Committee. Technical Report Series No. 701. Geneva: WHO.